Lactation inhibition by a single injection of a new depot-bromocriptine.
Recently, long-acting injectable forms of bromocriptine have become available for the prevention of lactation. The first developed depot-form was very effective, but had the disadvantage of a slowly metabolized carrier. we investigated the pharmacokinetics, efficacy, tolerance and safety of 40 and 50 mg of a new rapidly eliminated depot-form in 61 postpartum women. Bromocriptine rapidly increased after injection and prolactin was effectively suppressed during the study-period of 60 days. Overall efficacy was very good or good in 98% and no rebound lactation occurred. Sixteen women experienced side effects. Tolerance at the injection site was good and safety tests did not show abnormalities. There were no differences between the two dosages. We conclude that this new depot-bromocriptine is a safe, well tolerated and effective drug in the suppression of prolactin and the prevention of post-partum lactation.
Kremer
J A
JA
Department of Obstetrics and Gynaecology, St. Radboud University Hospital, Nijmegen, The Netherlands.
Rolland
R
R
van der Heijden
P F
PF
Schellekens
L A
LA
Vosmar
M B
MB
Lancranjan
I
I
D000328:Adult; D001971:Bromocriptine / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D003692:Delayed-Action Preparations; D003864:Depression, Chemical; D004334:Drug Administration Schedule; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007774:Lactation / Q000097:blood / Q000187:drug effects*; D049590:Postpartum Period / Q000097:blood; D011247:Pregnancy; D011388:Prolactin / Q000097:blood
D003692:Delayed-Action Preparations; D001971:Bromocriptine; D011388:Prolactin